Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy

Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy

Recurrent glioblastomas (rGBM) have dismal outcomes, but long-term survival has been observed in subsets of patients after immunotherapy. Here the authors report a positive association between low tumor mutation burden, inflammatory gene signatures, and survival after immunotherapy in rGBM patients.

Bibliographic Details
Main Authors: Matthias Gromeier, Michael C. Brown, Gao Zhang, Xiang Lin, Yeqing Chen, Zhi Wei, Nike Beaubier, Hai Yan, Yiping He, Annick Desjardins, James E. Herndon, Frederick S. Varn, Roel G. Verhaak, Junfei Zhao, Dani P. Bolognesi, Allan H. Friedman, Henry S. Friedman, Frances McSherry, Andrea M. Muscat, Eric S. Lipp, Smita K. Nair, Mustafa Khasraw, Katherine B. Peters, Dina Randazzo, John H. Sampson, Roger E. McLendon, Darell D. Bigner, David M. Ashley
Format: Article
Language:English
Published: Nature Publishing Group 2021-01-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-020-20469-6

Internet

https://doi.org/10.1038/s41467-020-20469-6

Similar Items